BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• Business

  Burning Rock Publishes 2023 Annual Report on Form 20-F

  Burning Rock Biotech Limited, a company focused on the application of next generation sequencing technology in the field of precision oncology, announces that on April 29, 2024 it filed its Annual Report on Form 20-F for the year ended December 31, 2023 with the U.S. Securities and Exchange Commission.

  April 29, 2024

   · 

  2 min read
• Policy

  ENA Respiratory Announces FDA IND Clearance for its Prophylactic Intranasal INNA-051 - a First-in-Class Antiviral Innate Immunomodulator

  ENA Respiratory announces that the U.S. Food and Drug Administration has issued a ‘safe to proceed’ notice for its investigational new drug application for a Phase 1b study of its novel dry powder formulation of INNA-051.

  April 29, 2024

   · 

  3 min read
• Immunovia publishes the annual report for 2023

  Immunovia AB announced that the Annual Report for 2023 has been published.

  April 29, 2024

   · 

  1 min read
• Drug Development

  MannKind Announces IND Clearance From U.S. FDA to Start Phase 3 Study of Clofazimine Inhalation Suspension for Nontuberculous Mycobacterial (NTM) Lung Disease

  MannKind Corporation announced that the U.S. Food and Drug Administration has cleared the company’s Investigational New Drug application for MNKD-101, enabling the initiation of a Phase 3 study for the treatment of nontuberculous mycobacterial lung disease.

  April 29, 2024

   · 

  4 min read
• Pharm Country

  Henry Schein to Present at Investor Conferences in May 2024

  Henry Schein, Inc. announced today that the Company will present at the following investor conferences in May.

  April 29, 2024

   · 

  2 min read
• Deals

  Donaldson Enters into Agreement to Acquire Minority Stake in Medica, S.p.A.

  Donaldson Company, Inc., a leading worldwide provider of innovative filtration products and solutions, announced it has entered into a definitive agreement allowing the Company to purchase a 49% stake in Medica S.p.A.

  April 29, 2024

   · 

  5 min read
• Business

  STAAR Surgical to Report First Quarter Results on May 7, 2024

  STAAR Surgical Company today announced that it will release financial results for the first quarter ended March 29, 2024, on Tuesday, May 7, 2024, after the market close.

  April 29, 2024

   · 

  2 min read
• Business

  Mosaic ImmunoEngineering Agrees to Acquire Clinical Necroptosis Cancer Therapy Assets from Oncotelic Therapeutics, Inc.

  Mosaic ImmunoEngineering, Inc today announced the signing of a binding term-sheet with Oncotelic Therapeutics, Inc.

  April 29, 2024

   · 

  6 min read
• Drug Development

  Intellia Therapeutics to Present Updated Data from Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the EAACI Congress 2024

  Intellia Therapeutics, Inc. today announced the acceptance of a oral presentation from the Phase 1 portion of the ongoing NTLA-2002 Phase 1/2 study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2024, taking place May 31 – June 3 in Valencia, Spain.

  April 29, 2024

   · 

  6 min read
• Business

  Immunovia appoints Dr. Lisa Ford as Clinical Laboratory Director

  Immunovia today announces the appointment of Dr. Lisa Ford as Clinical Laboratory Director.

  April 29, 2024

   · 

  2 min read